DENVER, Colo., 28 June, 2024 (247marketnews.com) – (Nasdaq:ESPR) are discussed in this article.
Esperion Therapeutics, Inc. (ESPR) has captured the attention of investors with a notable surge in its stock price, currently trading bullishly at $2.857 in the pre-market session, reflecting a substantial increase from the previous day’s close of $2.31. This positive momentum, supported by a trading volume of 1.2 million shares and a 25.41% rise from the market open, indicates a strong investor interest in Esperion Therapeutics, Inc. Investors are advised to track these developments closely as ESPR continues to exhibit a robust performance in the market.
In a strategic move to bolster its financial standing and advance its innovative therapies for cardiovascular and metabolic diseases, Esperion Therapeutics, Inc. has announced a significant agreement with OMERS Life Sciences. The deal entails the sale of Esperion’s European royalty rights related to bempedoic acid products to OMERS Life Sciences for an impressive sum of $304.7 million. As part of the agreement, OMERS Life Sciences will acquire these European royalties, with a provision for the royalties to revert back to Esperion upon OMERS Life Sciences achieving 1.7 times its investment. This collaboration with OMERS Life Sciences, a reputable investor in the life sciences sector, underscores Esperion’s dedication to driving growth and innovation in disease treatments.
Esperion’s leadership team views this agreement as a transformative step that will not only enhance the company’s financial outlook but also reinforce its commitment to delivering high-quality therapies to patients. This milestone transaction exemplifies Esperion’s strategic vision and signifies its ongoing efforts to address unmet medical needs in the healthcare landscape. For further information on this significant development, interested parties are encouraged to refer to the detailed article on Esperion Therapeutics, Inc.’s partnership with OMERS Life Sciences on globenewswire.com.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com